Gland Pharma Limited (GLAND)

About

Gland Pharma Limited is a pharmaceutical manufacturer in India's healthcare sector with a market cap of ₹49,008 Cr and recent quarterly revenues ranging ₹1,074–₹1,800 Cr (standalone basis, though consolidated figures also appear in the data). Operating margins vary 21–40% across quarters with net profit ranging ₹261–₹420 Cr. The company maintains a strong balance sheet (D/E 0.02) and pays dividends annually (Aug 2024, Aug 2025, Aug 2026).

Face value: ₹1

Market cap

₹47,428 Cr

P/E

42.0×

P/B

4.6×

Dividend yield

1.3%

ROE

10.5%

ROCE

14.8%

Debt / equity

0.02

OPM

25.3%

EPS (TTM)

₹68.5

Book value

₹628.5

52-week high

—

52-week low

Key insights

Company research notes and source-linked reviews

Key risks

Valuation: PE 43.42 is elevated for the pharma sector; verify if near-term earnings growth justifies the multiple.
Revenue instability: quarterly standalone revenue swings ₹1,074–₹1,695 Cr (58% range); understand drivers (seasonality, segment mix, geography) before forecasting.
Margin compression: OPM ranges 21–40% across quarters with consolidated at lower end; verify if this reflects structural competitive pressure or temporary operational factors.
Capital efficiency: ROE 10.53% trails OPM 25%+; audit capital deployment to understand why returns lag operating profitability.

Generated analysis · source review pending

Growth drivers

Quarterly data includes two revenue figures per period (₹1,100–₹1,800 Cr range), suggesting ₹500–₹700 Cr from consolidated/subsidiary operations; verify if these segments grow faster than standalone base.
Standalone OPM capability: Mar 2026 hit 40.24%; if factors that depressed OPM to 21% (Sep 2025) resolve, margin recovery on ₹1,400 Cr quarterly base could drive earnings without volume growth.
Market momentum: 1y return 51.71% signals investor confidence; verify if this reflects sector tailwinds (pharma exports, domestic consumption, specialty drugs growth) or company-specific catalysts.

Generated analysis · source review pending

1,445 historical price candles were omitted because the exchange source has not been verified.

₹2,874.4-3.9%1Y

Quick read

rule-based

Pros

+Healthy operating margin of 25.3%
+Almost debt-free (debt/equity 0)
+Comfortable interest coverage of 45.7×
+Dividend payout of 55.5% of profit

Cons

−Low return on equity of 9.2% (3-yr avg)

Research score

Structured signal from quality, growth, valuation and momentum.

58/100

Business quality: 64
Growth: 75
Valuation: 36

Revenue & net profit

₹ crore, by fiscal year

RevenuePAT

Margins

% of revenue, by fiscal year

OPMPAT margin

Peers

Comparable companies from the narrowest available industry classification.

Part ofNIFTY SMALLCAP 50 NIFTY SMALLCAP 100 NIFTY SMALLCAP 250 NIFTY MIDSMALLCAP 400 NIFTY 500

Screen this industry Compare top 5 side-by-side

Company	Mkt Cap	EV	Revenue	EBITDA	OPM	PAT	NPM	ROCE	ROE	WC Days
Torrent Pharmaceuticals LimitedTORNTPHARMTORNTPHARM	₹1,61,325 Cr	₹1,76,123 Cr	₹15,723 Cr	₹5,191 Cr	32.6%	₹2,181 Cr	15.3%	14.5%	27.1%	163
Zydus Lifesciences LimitedZYDUSLIFEZYDUSLIFE	₹1,14,284 Cr	₹1,26,053 Cr	₹28,592 Cr	₹8,316 Cr	31.2%	₹4,513 Cr	18.9%	23.4%	19.7%	212
Laurus Labs LimitedLAURUSLABSLAURUSLABS	₹1,07,176 Cr	₹1,09,573 Cr	₹7,270 Cr	₹2,034 Cr	26.1%	₹1,093 Cr	13.1%	21.3%	18.2%	263
Mankind Pharma LimitedMANKINDMANKIND	₹1,04,696 Cr	₹1,11,007 Cr	₹14,738 Cr	₹3,827 Cr	25.3%	₹2,068 Cr	13.6%	14.2%	12.5%	117
Aurobindo Pharma LimitedAUROPHARMAAUROPHARMA	₹97,389 Cr	₹1,05,065 Cr	₹34,935 Cr	₹7,085 Cr	20.3%	₹3,713 Cr	10.4%	14.7%	9.9%	252
Lupin LimitedLUPINLUPIN	₹92,866 Cr	₹98,777 Cr	₹29,967 Cr	₹9,538 Cr	31.5%	₹5,529 Cr	19.2%	34.2%	26.9%	181
Glenmark Pharmaceuticals LimitedGLENMARKGLENMARK	₹65,781 Cr	₹65,781 Cr	₹17,737 Cr	₹4,797 Cr	26.9%	₹1,496 Cr	8%	37.8%	0%	83
Alkem Laboratories LimitedALKEMALKEM	₹62,431 Cr	₹64,055 Cr	₹15,081 Cr	₹3,032 Cr	20.4%	₹2,158 Cr	16%	21.5%	17.8%	152
Biocon LimitedBIOCONBIOCON	₹60,413 Cr	₹75,238 Cr	₹17,321 Cr	₹3,536 Cr	20.4%	₹495 Cr	2.2%	3.9%	1.4%	85
Abbott India LimitedABBOTINDIAABBOTINDIA	₹56,901 Cr	—	₹4,310 Cr	₹921 Cr	27.3%	₹691 Cr	22.4%	44.1%	34.5%	110
Ipca Laboratories LimitedIPCALABIPCALAB	₹49,299 Cr	₹50,003 Cr	₹10,126 Cr	₹2,232 Cr	20.5%	₹1,310 Cr	12.3%	17.8%	15.2%	308
Gland Pharma LimitedGLANDGLAND	₹47,428 Cr	₹47,671 Cr	₹6,725 Cr	₹1,751 Cr	25.3%	₹1,129 Cr	16%	14.8%	10.5%	255

Loading peers…

Financials

Reported profit and loss, balance sheet, cash flow and growth history.

Annual Quarterly

Consolidated Standalone

Consolidated figures · ₹ crore

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	3,463	4,401	3,625	5,665	5,617	6,431
COGS	1,492	2,109	1,685	2,173	2,090	2,243
Gross profit	1,971	2,291	1,939	3,492	3,526	4,188
	669	781	914	2,159	2,257	2,558
	1,302	1,510	1,025	1,333	1,269	1,630
OPM %	37.6%	34.3%	28.3%	23.5%	22.6%	25.3%
Depreciation	99	110	147	345	378	424
Interest	3	5	7	26	42	33
	135	224	184	170	214	292
Profit before tax	1,335	1,619	1,055	1,133	1,063	1,465
Tax	338	407	274	360	364	437
Tax %	25.3%	25.1%	25.9%	31.8%	34.3%	29.9%
	997	1,212	781	772	699	1,027
PAT margin %	28.8%	27.5%	21.6%	13.6%	12.4%	16%
EPS (₹)	63.1	73.8	47.4	46.9	42.4	62.4
EPS adjusted (₹)	60.9	73.8	47.4	46.9	42.4	62.3
	0%	0%	0%	42.6%	42.5%	32.1%
Annual report	Annual report for Mar 2021	Annual report for Mar 2022	Annual report for Mar 2023	Annual report for Mar 2024	Annual report for Mar 2025	Annual report for Mar 2026

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity capital	16	16	16	16	16	16
Reserves	5,887	7,141	7,942	8,707	9,134	10,341
	4	4	4	320	269	243
	589	672	815	1,618	1,805	1,910
Total equity & liabilities	6,496	7,834	8,778	10,661	11,225	12,511
	954	1,502	1,570	3,896	4,104	4,454
CWIP	338	181	177	238	151	342
Investments	0	155	0	0	0	0
	5,204	5,996	7,030	6,528	6,970	7,714
Total assets	6,496	7,834	8,778	10,661	11,225	12,511

Loading financials…

Ratios

Annual operating, return, leverage and working-capital ratios.

Consolidated Standalone

Consolidated figures

Ratio	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Margins
Gross margin %	56.9%	52.1%	53.5%	61.6%	62.8%	65.1%

Loading ratios…

Shareholding

Quarterly ownership, named holders, insider transactions and disclosed deals.

Quarterly Annual

Every quarter filed · % of equity

Holder (%)	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	57.86%	57.86%	57.86%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.83%	51.77%
	4.91%	4.04%	3.59%	6.88%	4.47%	5.04%	6.9%	7.39%	7.91%	7.58%	7.3%	8.74%
	22.45%	24.17%	25.23%	32.83%	35.37%	34.8%	33.27%	32.85%	32.64%	32.98%	33.35%	30.44%
Government	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	14.78%	13.93%	13.32%	8.46%	8.33%	8.33%	8%	7.93%	7.62%	7.61%	7.52%	9.05%
No. of shareholders	—	—	—	—	—	—	—	—	97,151	94,578	91,500	1,08,266

Promoter holding down 6.09 percentage points since Sep 2023.

1 disclosure

Person	Deal	Shares	Value	Holding	Filed
A. JAYATHEERTHAEmployees/Designated Employees	SellMarket Sale	191	₹3.8 L	0.00% → 0.00%	29 Sept 20257(2)

Disclosed under SEBI’s insider-trading regulations, which require a filing only above ₹10 lakh in a quarter — smaller dealings are in no disclosure. Holdings are the filer’s own percentages, not recomputed.

43 deals · 2 Sept 2021 – 17 Sept 2026

Date	Client	Type	Venue	Side	Quantity	Price	Value
17 Sept 2026	BOFA SECURITIES EUROPE SA	Block	NSE	Buy	1,50,000	₹2,826.60	₹42.40 Cr
17 Sept 2026	NORTH ROCK SG VCC	Block	NSE	Sell	1,50,000	₹2,826.60	₹42.40 Cr
4 Sept 2026	FOSUN PHARMA INDUSTRIAL PTE. LTD.	Bulk	BSE	Sell	76,05,500	₹2,827.38	₹2,150.36 Cr
4 Sept 2026	KOTAK MAHINDRA MUTUAL FUND	Bulk	BSE	Buy	27,93,000	₹2,826.60	₹789.47 Cr
4 Sept 2026	KOTAK MAHINDRA MUTUAL FUND	Block	BSE	Buy	27,93,000	₹2,826.60	₹789.47 Cr
4 Sept 2026	FOSUN PHARMA INDUSTRIAL PTE. LTD.	Block	BSE	Sell	27,93,000	₹2,826.60	₹789.47 Cr
4 Sept 2026	FOSUN PHARMA INDUSTRIAL PTE. LTD.	Bulk	BSE	Sell	22,91,500	₹2,833.45	₹649.29 Cr
4 Sept 2026	AXIS MUTUAL FUND	Block	BSE	Buy	13,57,000	₹2,826.60	₹383.57 Cr
4 Sept 2026	AXIS MUTUAL FUND	Bulk	BSE	Buy	13,57,000	₹2,826.60	₹383.57 Cr
4 Sept 2026	FOSUN PHARMA INDUSTRIAL PTE. LTD.	Block	BSE	Sell	13,57,000	₹2,826.60	₹383.57 Cr

1–10 of 43

1 / 5

Mr. Srinivas SaduExecutive Director-Chairperson
Mr. UDO JAHANNES VETTERNon-Executive - Independent Director
Mr. Essaji Goolam VahanvatiNon-Executive - Independent Director
Ms. Naina Lal KidwaiNon-Executive - Independent Director
Mr. Jia Ai ZhangNon-Executive - Non Independent Director
Mr. Wenjie ZhangNon-Executive - Non Independent Director
Ms. Wei HuangNon-Executive - Non Independent Director
Mr. William Robert KellerNon-Executive - Independent Director
Sampath Kumar PallerlamudiCompany Secretary & Compliance Officer

Current officeholders as filed with BSE. A person holding two offices is listed once per office.

Loading shareholding…

F&O

Current futures and options contracts with compact option-chain pages.

Not in the F&O segment

Only about 210 stocks have listed futures and options. Contracts appear here for those, refreshed after each close.

Loading f&o…

Fund holders

Mutual-fund schemes that disclosed a holding in the company.

Portfolio month

Schemes holding

64

across 12 fund houses

Held by these funds

11.74%

of the company's equity

All mutual funds

28.23%

shareholding pattern, Jun 2026

Portfolios as of

August 2026

compared with July 2026

64 schemes · 12 fund houses

		Shares
Large and Midcap Fund	SBI Mutual Fund	31.87 L	919.59	2.17%	1.931%	+16,587
Growth Mid Cap FundNEW	Nippon India Mutual Fund	28 L	808.02	1.55%	1.697%	—
SMALL CAP FUND	Nippon India Mutual Fund	18.32 L	528.8	0.64%	1.111%	-0
India Opportunities Fund	ICICI Prudential Mutual Fund	13.42 L	387.21	1.01%	0.813%	-10.62 L
Small Cap Fund	DSP Mutual Fund	13.16 L	379.72	1.75%	0.797%	-0
Multi Cap FundNEW	Nippon India Mutual Fund	11.94 L	344.52	0.61%	0.724%	—
Contra Fund	SBI Mutual Fund	11.13 L	321.2	0.67%	0.675%	-0
ELSS Tax Saver Fund	Nippon India Mutual Fund	11 L	317.44	2.16%	0.667%	-0

1–8 of 64

1 / 8

Loading fund holders…

Documents

Annual reports, exchange filings, offer documents, ratings and earnings-call material.

Announcements

30

Annual reports

6

Investor Presentation and earnings call

5

Aug 2026Transcript AI Summary PPT REC
May 2026Transcript AI Summary PPT

Documents link to external sources (exchange filings, company investor pages).

Loading documents…

Events

Upcoming dates and the company’s corporate-action history.

3

Final dividend11 Aug 2026 · ex-date₹20
Final dividend14 Aug 2025 · ex-date₹18
Final dividend16 Aug 2024 · ex-date₹20

1

Board meeting to consider results10 Aug 2026

Loading events…

Announcements

Latest exchange announcements, filings and downloadable documents.

1 month 3 months 6 months 1 year All

48 announcementsExport CSV

1 Oct 2026, 3:54 pmCompany Update

Announcement under Regulation 30 (LODR)-Change in Directorate

Change in Directorate PDF

1 Oct 2026, 3:51 pmCompany Update

Announcement under Regulation 30 (LODR)-Updates on Acquisition

Acquisition PDF

1 Oct 2026, 3:45 pmOthers

Board Meeting Outcome for Outcome Of Board Meeting - 01-10-2026

Outcome without intimation PDF

1 Oct 2026, 8:56 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

30 Sept 2026, 2:28 pmInsider Trading / SAST

Closure of Trading Window

Closure of Trading Window PDF

30 Sept 2026, 11:39 amInsider Trading / SAST

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011

Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011 PDF

29 Sept 2026, 2:53 pmCompany Update

Announcement under Regulation 30 (LODR)-Newspaper Publication

Newspaper Publication PDF

13 Sept 2026, 4:32 pmCompany Update

Announcement under Regulation 30 (LODR)-Acquisition

Acquisition PDF

Date	Category	Subject	Filing
1 Oct 2026, 3:54 pm	Company Update Change in Directorate	Announcement under Regulation 30 (LODR)-Change in Directorate	PDF
1 Oct 2026, 3:51 pm	Company Update Acquisition	Announcement under Regulation 30 (LODR)-Updates on Acquisition

Loading announcements…

Leverage
Current ratio	10	10.05	9.46	4.04	4.33	4.68

Return ratios
Return on assets %	15.3%	15.5%	8.9%	7.2%	6.2%	8.2%

₹ Cr	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	605	791	364	997	915	1,031
	-1,524	-1,003	1,208	-1,757	1,705	138
	1,238	35	15	-799	-433	-417
Net cash flow	319	-177	1,587	-1,560	2,186	752
Free cash flow	376	279	143	607	530	541
CFO / Operating profit %	46.5%	52.4%	35.5%	74.8%	72.1%	63.3%

Gland Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Ratios

Shareholding

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

3

1

Announcements

Not in the F&O segment

3

1

Announcements

Annual reports

Investor Presentation and earnings call

Compounded sales growth

Compounded profit growth

Return on equity

Working capital
Receivable days	71	99	88	100	99	107

Gland Pharma Limited

About

Key insights

Key risks

Growth drivers

Quick read

Pros

Cons

Research score

Revenue & net profit

Margins

Peers

Financials

Profit & loss

Balance sheet

Ratios

Ratio timeline

Shareholding

Quarterly record

Insider dealing

Bulk & block deals

Board and management

F&O

Not in the F&O segment

Fund holders

Documents

Announcements

Annual reports

Investor Presentation and earnings call

Events

Dividends3

Board meetings1

Announcements

Not in the F&O segment

Quarterly record

Insider dealing

Bulk & block deals

Board and management

Ratio timeline

Dividends3

Board meetings1

Announcements

Annual reports

Investor Presentation and earnings call

Profit & loss

Balance sheet

Cash flow

Compounded returns

Compounded sales growth

Compounded profit growth

Return on equity

3

1

3

1